Department of Biotechnology, Aarupadai Institute of Technology, Vinayaka Missions University, Chennai, India.
Curr Pharm Biotechnol. 2022;23(11):1336-1345. doi: 10.2174/1389201023666220104143113.
Cardiovascular diseases, like coronary heart disease or artery disorders (arteriosclerosis, including artery solidification), heart failure (myocardial infarction), arrhythmias, congestive heart condition, stroke, elevated vital signs (hypertension), rheumatic heart disorder, and other circulatory system dysfunctions are the most common causes of death worldwide. Cardiovascular disorders are treated with stenting, coronary bypass surgery grafting, anticoagulants, antiplatelet agents, and other pharmacological and surgical procedures; however, these have limitations due to their adverse effects. Fibrinolytic agents degrade fibrin through enzymatic and biochemical processes. There are various enzymes that are currently used as a treatment for CVDs, like streptokinase, nattokinase, staphylokinase, urokinase, etc. These enzymes are derived from various sources, like bacteria, fungi, algae, marine organisms, plants, snakes, and other organisms. This review deals with the fibrinolytic enzymes, their mechanisms, sources, and their therapeutic potential.
心血管疾病，如冠心病或动脉疾病（动脉硬化，包括动脉僵化）、心力衰竭（心肌梗死）、心律失常、充血性心脏状况、中风、生命体征升高（高血压）、风湿性心脏病和其他循环系统功能障碍，是全球最常见的死亡原因。心血管疾病的治疗方法包括支架置入、冠状动脉旁路移植术、抗凝剂、抗血小板药物和其他药理学及手术程序；然而，由于其副作用，这些方法存在局限性。纤维蛋白溶解剂通过酶和生化过程降解纤维蛋白。目前有多种酶被用作 CVD 的治疗方法，如链激酶、纳豆激酶、葡萄球菌激酶、尿激酶等。这些酶来源于不同的来源，如细菌、真菌、藻类、海洋生物、植物、蛇类和其他生物体。本综述涉及纤维蛋白溶解酶、它们的机制、来源及其治疗潜力。
